$DVA
DAVITA INC. Stock $dva

$dva Overview Financials Valuation SEC Filings Company Website

2012 Q4 Form 10-Q Financial Statement

#000119312512443449 Filed on October 31, 2012

Income Statement

Concept	2012 Q4	2012 Q3	2011 Q4
Revenue	$2.478B	$1.946B	$1.662B
YoY Change	49.1%	10.7%	0.91%
Cost Of Revenue	$1.708B	$1.327B	$1.167B
YoY Change	46.34%	11.58%	2.98%
Gross Profit	$770.4M	$618.5M	$495.2M
YoY Change	55.57%	8.85%	-3.64%
Gross Profit Margin	31.09%	31.78%	29.8%
Selling, General & Admin	$274.6M	$199.3M	$96.80M
YoY Change	183.68%	8.02%	-51.79%
% of Gross Profit	35.64%	32.22%	19.55%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$109.5M	$80.60M	$73.00M
YoY Change	50.0%	18.88%	21.46%
% of Gross Profit	14.21%	13.03%	14.74%
Operating Expenses	$383.9M	$279.4M	$167.3M
YoY Change	129.47%	10.83%	-35.8%
Operating Profit	$388.1M	$340.9M	$329.7M
YoY Change	17.69%	7.06%	29.18%
Interest Expense	-$98.80M	-$67.40M	-$59.60M
YoY Change	65.77%	15.81%	14.84%
% of Operating Profit	-25.46%	-19.77%	-18.08%
Other Income/Expense, Net	$1.000M	$819.0K	$800.0K
YoY Change	25.0%	2.38%	-27.27%
Pretax Income	$282.2M	$271.2M	$268.8M
YoY Change	4.98%	4.98%	103.28%
Income Tax	$97.90M	$98.65M	$101.3M
% Of Pretax Income	34.7%	36.37%	37.69%
Net Earnings	$155.8M	$144.7M	$148.1M
YoY Change	5.21%	6.91%	114.61%
Net Earnings / Revenue	6.29%	7.44%	8.91%
Basic Earnings Per Share	$0.77	$0.76	$1.59
Diluted Earnings Per Share	$0.75	$0.75	$1.56
COMMON SHARES
Basic Shares Outstanding	95.40M shares	190.0M shares
Diluted Shares Outstanding		193.3M shares

Balance Sheet

Concept	2012 Q4	2012 Q3	2011 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$541.0M	$388.0M	$411.0M
YoY Change	31.63%	-31.45%	-53.45%
Cash & Equivalents	$533.7M	$382.2M	$393.8M
Short-Term Investments	$7.000M	$6.000M	$17.00M
Other Short-Term Assets	$201.6M	$46.99M	$49.35M
YoY Change	308.46%	-85.5%	12.17%
Inventory	$78.13M	$78.32M	$75.73M
Prepaid Expenses	$75.85M		$48.26M
Receivables	$1.424B	$1.248B	$1.195B
Other Receivables	$321.0M	$241.0M	$282.0M
Total Short-Term Assets	$2.887B	$2.326B	$2.293B
YoY Change	25.89%	-1.87%	-12.57%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.872B	$1.655B	$1.433B
YoY Change	30.69%	23.85%	22.36%
Goodwill	$8.953B	$5.325B	$4.947B
YoY Change	80.97%		20.91%
Intangibles	$2.128B	$177.5M	$159.5M
YoY Change	1234.32%		-1.93%
Long-Term Investments	$94.00M	$42.00M	$37.00M
YoY Change	154.05%	7.69%	5.71%
Other Assets	$79.85M	$30.56M	$34.23M
YoY Change	133.28%	-4.51%	6.79%
Total Long-Term Assets	$13.13B	$8.498B	$6.611B
YoY Change	98.58%	34.11%	20.38%
TOTAL ASSETS
Total Short-Term Assets	$2.887B	$2.326B	$2.293B
Total Long-Term Assets	$13.13B	$8.498B	$6.611B
Total Assets	$16.01B	$10.82B	$8.904B
YoY Change	79.86%	24.32%	9.73%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$414.1M	$272.6M	$289.7M
YoY Change	42.98%	5.26%	60.0%
Accrued Expenses	$567.0M	$529.0M	$616.0M
YoY Change	-7.95%	14.5%	89.54%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$228.0M	$117.8M	$87.35M
YoY Change	161.03%	43.68%	16.63%
Total Short-Term Liabilities	$2.016B	$1.337B	$1.165B
YoY Change	73.12%	10.85%	26.01%
LONG-TERM LIABILITIES
Long-Term Debt	$8.327B	$5.621B	$4.418B
YoY Change	88.49%	27.25%	4.34%
Other Long-Term Liabilities	$443.7M	$145.2M	$132.0M
YoY Change	236.15%	-6.89%	47.84%
Total Long-Term Liabilities	$443.7M	$5.766B	$4.550B
YoY Change	-90.25%	26.09%	5.24%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.016B	$1.337B	$1.165B
Total Long-Term Liabilities	$443.7M	$5.766B	$4.550B
Total Liabilities	$11.52B	$7.604B	$6.157B
YoY Change	87.04%	13.37%	8.14%
SHAREHOLDERS EQUITY
Retained Earnings	$3.732B	$3.576B	$3.196B
YoY Change	16.77%		17.59%
Common Stock	$270.0K	$135.0K	$135.0K
YoY Change	100.0%		0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$1.162B	$1.564B	$1.632B
YoY Change	-28.77%		19.93%
Treasury Stock Shares	58.73M shares	39.52M shares	41.22M shares
Shareholders Equity	$3.763B	$2.537B	$2.141B
YoY Change
Total Liabilities & Shareholders Equity	$16.01B	$10.82B	$8.904B
YoY Change	79.86%	24.32%	9.73%

Cashflow Statement

Concept	2012 Q4	2012 Q3	2011 Q4
OPERATING ACTIVITIES
Net Income	$155.8M	$144.7M	$148.1M
YoY Change	5.21%	6.91%	114.61%
Depreciation, Depletion And Amortization	$109.5M	$80.60M	$73.00M
YoY Change	50.0%	18.88%	21.46%
Cash From Operating Activities	$200.2M	$366.6M	$150.6M
YoY Change	32.93%	-25.97%	24.88%
INVESTING ACTIVITIES
Capital Expenditures	-$171.2M	-$128.4M	-$148.3M
YoY Change	15.44%	32.37%	42.32%
Acquisitions
YoY Change
Other Investing Activities	-$3.875B	-$71.10M	-$118.0M
YoY Change	3183.47%	-90.23%	150.53%
Cash From Investing Activities	-$4.046B	-$199.6M	-$266.2M
YoY Change	1419.8%	-75.79%	75.94%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	3.998B	-58.50M	-31.90M
YoY Change	-12632.6%	-141.61%	-108.95%
NET CHANGE
Cash From Operating Activities	200.2M	366.6M	150.6M
Cash From Investing Activities	-4.046B	-199.6M	-266.2M
Cash From Financing Activities	3.998B	-58.50M	-31.90M
Net Change In Cash	152.4M	108.5M	-147.5M
YoY Change	-203.32%	-157.53%	-145.3%
FREE CASH FLOW
Cash From Operating Activities	$200.2M	$366.6M	$150.6M
Capital Expenditures	-$171.2M	-$128.4M	-$148.3M
Free Cash Flow	$371.4M	$495.0M	$298.9M
YoY Change	24.26%	-16.41%	32.96%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2011Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	541206000
CY2012Q3	dva	Line Of Credit Facility Additional Borrowing Capacity LineOfCreditFacilityAdditionalBorrowingCapacity	3000000000
CY2012Q3	us-gaap	Goodwill Goodwill	5324960000
CY2012Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	130897000
CY2012Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	5745136000
CY2012Q3	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	323219000
CY2012Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	416897000
CY2012Q3	us-gaap	Other Assets Current OtherAssetsCurrent	46989000
CY2012Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	30558000
CY2012Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	680765000
CY2012Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	19153000
CY2012Q3	us-gaap	Stockholders Equity StockholdersEquity	2537421000
CY2012Q3	us-gaap	Variable Interest Entity Consolidated Carrying Amount Assets VariableInterestEntityConsolidatedCarryingAmountAssets	21000000
CY2012Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2012Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	67623000
CY2012Q3	us-gaap	Available For Sale Securities Gross Unrealized Gain Loss AvailableForSaleSecuritiesGrossUnrealizedGainLoss	1893000
CY2012Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	8496000
CY2012Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	2670385000
CY2012Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	450000000	shares
CY2012Q3	us-gaap	Temporary Equity Carrying Amount Attributable To Noncontrolling Interest TemporaryEquityCarryingAmountAttributableToNoncontrollingInterest	550020000
CY2012Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	529492000
CY2012Q3	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	6599000
CY2012Q3	us-gaap	Treasury Stock Shares TreasuryStockShares	39515303	shares
CY2012Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	95346980	shares
CY2012Q3	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	10059000
CY2012Q3	us-gaap	Variable Interest Entity Consolidated Carrying Amount Liabilities VariableInterestEntityConsolidatedCarryingAmountLiabilities	18000000
CY2012Q3	us-gaap	Liabilities Liabilities	7603707000
CY2012Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	272627000
CY2012Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	145246000
CY2012Q3	us-gaap	Senior Notes SeniorNotes	2800000000
CY2012Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2012Q3	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	33625000
CY2012Q3	us-gaap	Long Term Investments LongTermInvestments	13249000
CY2012Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	3575996000
CY2012Q3	us-gaap	Assets Assets	10824112000
CY2012Q3	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	484918000
CY2012Q3	us-gaap	Longterm Debt Weighted Average Interest Rate LongtermDebtWeightedAverageInterestRate	0.0538	pure
CY2012Q3	us-gaap	Investments Investments	19085000
CY2012Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1248050000
CY2012Q3	us-gaap	Inventory Net InventoryNet	78322000
CY2012Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2012Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	10824112000
CY2012Q3	us-gaap	Long Term Debt LongTermDebt	5738537000
CY2012Q3	us-gaap	Minority Interest MinorityInterest	132964000
CY2012Q3	us-gaap	Treasury Stock Value TreasuryStockValue	1564178000
CY2011Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2012Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1268767000
CY2012Q3	us-gaap	Line Of Credit Facility Remaining Borrowing Capacity LineOfCreditFacilityRemainingBorrowingCapacity	350000000
CY2012Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	382194000
CY2012Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	134862283	shares
CY2012Q3	us-gaap	Capital Lease Obligations CapitalLeaseObligations	77585000
CY2012Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	177542000
CY2012Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	180834000
CY2012Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-18283000
CY2012Q3	us-gaap	Investments And Other Noncurrent Assets InvestmentsAndOtherNoncurrentAssets	1341279000
CY2012Q3	us-gaap	Liabilities Current LiabilitiesCurrent	1336837000
CY2012Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	232127000
CY2012Q3	us-gaap	Short Term Investments ShortTermInvestments	5836000
CY2012Q3	us-gaap	Common Stock Value CommonStockValue	135000
CY2012Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2012Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	1864207000
CY2012Q3	us-gaap	Assets Current AssetsCurrent	2325674000
CY2012Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2012Q3	us-gaap	Preferred Stock Value PreferredStockValue
CY2012Q3	us-gaap	Other Receivables OtherReceivables	207439000
CY2012Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1654657000
CY2012Q3	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	28705000
CY2012Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	117821000
CY2012Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	543751000
CY2012Q3	us-gaap	Other Commitment OtherCommitment	3000000
CY2012Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	5620716000
CY2012Q3	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	4119000
CY2012Q3	dva	Certificates Of Deposit Money Market Funds And United States Government Securities CertificatesOfDepositMoneyMarketFundsAndUnitedStatesGovernmentSecurities	4636000
CY2012Q3	dva	Alliance And Product Supply Agreement Net AllianceAndProductSupplyAgreementNet	15990000
CY2012Q3	dva	Long Term Debt And Other Noncurrent LongTermDebtAndOtherNoncurrent	6266870000
CY2012Q3	dva	Mutual Fund Investments At Fair Value MutualFundInvestmentsAtFairValue	14449000
CY2012Q3	dva	Acquisition Obligations And Other Notes Payable AcquisitionObligationsAndOtherNotesPayable	37676000
CY2012Q3	dva	Long Term Debt Maturities Repayments Of Principal In Year Six And Thereafter LongTermDebtMaturitiesRepaymentsOfPrincipalInYearSixAndThereafter	2860784000
CY2012Q3	dva	Investments And Other Current Assets InvestmentsAndOtherCurrentAssets	695430000
CY2012Q3	dva	Held To Maturity Securities Released From Regulatory Agencies HeldToMaturitySecuritiesReleasedFromRegulatoryAgencies	7100000
CY2012Q3	dva	Line Of Credit Weighted Average Interest Rate LineOfCreditWeightedAverageInterestRate	0.0461	pure
CY2012Q3	dva	Percentage Of Outstanding Patient Accounts Receivables PercentageOfOutstandingPatientAccountsReceivables	1.00	pure
CY2012Q3	dva	Accounts Receivable Months Outstanding AccountsReceivableMonthsOutstanding	P4M
CY2012Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	95400000	shares
CY2010Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	860117000
CY2011Q4	us-gaap	Goodwill Goodwill	4946976000
CY2011Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	4512811000
CY2011Q4	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	280382000
CY2011Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	325734000
CY2011Q4	us-gaap	Other Assets Current OtherAssetsCurrent	49349000
CY2011Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	34231000
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	2141075000
CY2011Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2011Q4	us-gaap	Available For Sale Securities Gross Unrealized Gain Loss AvailableForSaleSecuritiesGrossUnrealizedGainLoss	-255000
CY2011Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	2268125000
CY2011Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	450000000	shares
CY2011Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	37412000
CY2011Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Noncontrolling Interest TemporaryEquityCarryingAmountAttributableToNoncontrollingInterest	478216000
CY2011Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	412972000
CY2011Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	7842000
CY2011Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	41220920	shares
CY2011Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	93641363	shares
CY2011Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	8943000
CY2011Q4	us-gaap	Liabilities Liabilities	6145831000
CY2011Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	289653000
CY2011Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	132006000
CY2011Q4	us-gaap	Senior Notes SeniorNotes	1550000000
CY2011Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2011Q4	us-gaap	Long Term Investments LongTermInvestments	9890000
CY2011Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	3195818000
CY2011Q4	us-gaap	Assets Assets	8892172000
CY2011Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	423098000
CY2011Q4	us-gaap	Investments Investments	27289000
CY2011Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1195163000
CY2011Q4	us-gaap	Inventory Net InventoryNet	75731000
CY2011Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2011Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8892172000
CY2011Q4	us-gaap	Long Term Debt LongTermDebt	4504969000
CY2011Q4	us-gaap	Minority Interest MinorityInterest	127050000
CY2011Q4	us-gaap	Treasury Stock Value TreasuryStockValue	1631694000
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	393752000
CY2011Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	134862283	shares
CY2011Q4	us-gaap	Capital Lease Obligations CapitalLeaseObligations	43364000
CY2011Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	159491000
CY2011Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-19484000
CY2011Q4	us-gaap	Investments And Other Noncurrent Assets InvestmentsAndOtherNoncurrentAssets	71446000
CY2011Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1153116000
CY2011Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	250343000
CY2011Q4	us-gaap	Short Term Investments ShortTermInvestments	17399000
CY2011Q4	us-gaap	Common Stock Value CommonStockValue	135000
CY2011Q4	us-gaap	Assets Current AssetsCurrent	2281608000
CY2011Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2011Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	27325000
CY2011Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2011Q4	us-gaap	Other Receivables OtherReceivables	269832000
CY2011Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1432651000
	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	632124000
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment On Derivatives Included In Net Income Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentOnDerivativesIncludedInNetIncomeNetOfTax	7124000
	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	-27839000
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-2228000
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	399491000
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.40
	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	2675000
CY2011Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	87345000
CY2011Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	596300000
CY2011Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	4417624000
CY2011Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	3420000
CY2011Q4	dva	Certificates Of Deposit Money Market Funds And United States Government Securities CertificatesOfDepositMoneyMarketFundsAndUnitedStatesGovernmentSecurities	11754000
CY2011Q4	dva	Alliance And Product Supply Agreement Net AllianceAndProductSupplyAgreementNet	19987000
CY2011Q4	dva	Long Term Debt And Other Noncurrent LongTermDebtAndOtherNoncurrent	4992715000
CY2011Q4	dva	Mutual Fund Investments At Fair Value MutualFundInvestmentsAtFairValue	15535000
CY2011Q4	dva	Acquisition Obligations And Other Notes Payable AcquisitionObligationsAndOtherNotesPayable	37447000
CY2011Q4	dva	Investments And Other Current Assets InvestmentsAndOtherCurrentAssets	692693000
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-2447000
	us-gaap	Costs And Expenses CostsAndExpenses	4180706000
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	14502000
	us-gaap	Operating Income Loss OperatingIncomeLoss	800670000
	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	13766000
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	67385000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	56652000
	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	29740000
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	27350513000
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	332325000
	us-gaap	Employee Service Share Based Compensation Cash Received From Exercise Of Stock Options EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions	5443000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	308519000
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-353065000
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	67385000
	us-gaap	Minority Interest Period Increase Decrease MinorityInterestPeriodIncreaseDecrease	-5811000
	us-gaap	Share Based Compensation ShareBasedCompensation	36392000
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	4727000
	us-gaap	Profit Loss ProfitLoss	397263000
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	323348000
	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	4981376000
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2005000	shares
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	193641000
	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	51623000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	9886000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1029387000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1133007000
	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax	-3688000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	251879000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-318911000
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities	29747000
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	121631000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	498033000
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	27506051000
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-2408000
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	97057773	shares
	us-gaap	Minority Interest Change In Redemption Value MinorityInterestChangeInRedemptionValue	103000
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	2195000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	61483000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	623525000
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-21359000
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.47
	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	4749469000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-215291000
	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	9190000
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment For Sale Of Securities Included In Net Income Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentForSaleOfSecuritiesIncludedInNetIncomeNetOfTax	-57000
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	3.50
	us-gaap	Health Care Organization Patient Service Revenue Less Provision For Bad Debts HealthCareOrganizationPatientServiceRevenueLessProvisionForBadDebts	4610949000
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	2118000
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment For Sale Of Securities Included In Net Income Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentForSaleOfSecuritiesIncludedInNetIncomeBeforeTax	93000
	us-gaap	Payments Of Dividends Minority Interest PaymentsOfDividendsMinorityInterest	67408000
	us-gaap	Health Care Organization Other Revenue HealthCareOrganizationOtherRevenue	370427000
	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	19640000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	95053339	shares
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-11767000
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	6555000
	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	1149000
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	38377000
	us-gaap	Tax Benefit From Stock Options Exercised1 TaxBenefitFromStockOptionsExercised1	35096000
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1777000	shares
	us-gaap	Net Income Loss NetIncomeLoss	329878000
	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	19640000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	224034000
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	24000000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	329981000
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	3.43
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	375904000
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-8733000
	us-gaap	Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Net Of Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax	1460000
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-587000
	us-gaap	Payments To Acquire Businesses And Interest In Affiliates PaymentsToAcquireBusinessesAndInterestInAffiliates	927124000
	us-gaap	Contributions From Noncontrolling Interests ContributionsFromNoncontrollingInterests	14779000
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	88454000
	dva	Increase Decrease In Other Current Receivables And Other Current Assets IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets	-81737000
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	329981000
	dva	Proceeds From Repayments Of Long Term Debt ProceedsFromRepaymentsOfLongTermDebt	137774000
	dva	Patient Care Costs PatientCareCosts	3466860000
	dva	Debt Expense DebtExpense	179340000
	dva	Adjustment Income Loss From Equity Method Investments AdjustmentIncomeLossFromEquityMethodInvestments	-238000
	dva	Adjustment Depreciation And Amortization AdjustmentDepreciationAndAmortization	194328000
	dva	Distributions From Equity Investments DistributionsFromEquityInvestments	340000
	dva	Changes From Net Income Attributable To Parent And Transfers From To Noncontrolling Interests ChangesFromNetIncomeAttributableToParentAndTransfersFromToNoncontrollingInterests	324067000
	dva	Gain Loss On Disposal Of Assets And Other Noncash Charges GainLossOnDisposalOfAssetsAndOtherNoncashCharges	16398000
	dva	Debt Expense And Redemption Charges DebtExpenseAndRedemptionCharges	179340000
	dva	Income Loss From Continuing Operations Available To Common Stockholders Basic IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic	332428000
	dva	Income Loss From Continuing Operations Available To Common Stockholders Diluted IncomeLossFromContinuingOperationsAvailableToCommonStockholdersDiluted	332428000
	dva	Weighted Average Number Basic Shares Outstanding Adjustment WeightedAverageNumberBasicSharesOutstandingAdjustment	95050000	shares
	dva	Stock Issued Or Vested During Period Shares Stock Awards StockIssuedOrVestedDuringPeriodSharesStockAwards	3000	shares
	dva	Health Care Organization Revenue Before Provision For Uncollectible Accounts HealthCareOrganizationRevenueBeforeProvisionForUncollectibleAccounts	5119896000
	dva	Goodwill Impairment Charges GoodwillImpairmentCharges	24000000
	dva	Payments For Proceeds To Acquire Equity Method Investments And Other Assets PaymentsForProceedsToAcquireEquityMethodInvestmentsAndOtherAssets	5005000
	dva	Payments For Proceeds From Sale Of Investments In Securities And Other PaymentsForProceedsFromSaleOfInvestmentsInSecuritiesAndOther	5627000
	dva	Payments For Proceeds Of Interest Rate Cap Premium And Other Deferred Financing Costs PaymentsForProceedsOfInterestRateCapPremiumAndOtherDeferredFinancingCosts	17863000
	dva	Provision For Doubtful Accounts On Patient Service Revenue ProvisionForDoubtfulAccountsOnPatientServiceRevenue	138520000
	dei	Trading Symbol TradingSymbol	DVA
	dei	Entity Registrant Name EntityRegistrantName	DAVITA INC
	dei	Amendment Flag AmendmentFlag	false
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2012
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2012-09-30
	dei	Entity Central Index Key EntityCentralIndexKey	0000927066
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	us-gaap	Costs And Expenses CostsAndExpenses	4849880000
	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.0531	pure
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	5064000
	us-gaap	Operating Income Loss OperatingIncomeLoss	909461000
	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	12992000
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	77259000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-18200000
	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	5257000
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	25799807000
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	380178000
	us-gaap	Employee Service Share Based Compensation Cash Received From Exercise Of Stock Options EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions	2174000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	381379000
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-1295555000
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	77259000
	us-gaap	Minority Interest Period Increase Decrease MinorityInterestPeriodIncreaseDecrease	-10765000
	us-gaap	Share Based Compensation ShareBasedCompensation	34857000
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	457437000
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.96
	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	1844000
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	6294000
	us-gaap	Profit Loss ProfitLoss	457437000
	us-gaap	Significant Supply Commitment Description SignificantSupplyCommitmentDescription	Certain consolidated joint ventures are contractually scheduled to dissolve after terms ranging from ten to fifty years.
	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	5759341000
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1815000	shares
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	234368000
	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	2118000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	8395000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	900613000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-786757000
	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	443176000
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment On Derivatives Included In Net Income Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentOnDerivativesIncludedInNetIncomeNetOfTax	7586000
	us-gaap	Proceeds From Repayments Of Restricted Cash Financing Activities ProceedsFromRepaymentsOfRestrictedCashFinancingActivities	-1268767000
	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	-6104000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	378949000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-11558000
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities	12375000
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	113101000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	623208000
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	26992105000
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-3429000
	us-gaap	Allowance For Doubtful Accounts Receivable Period Increase Decrease AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease	18216000
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y2M12D
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	96124226	shares
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	2698000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	51349000
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1593000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	719575000
	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	39346000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	94309099	shares
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	1201000
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	4.03
	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	5410200000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-125457000
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	2271000
	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	1116000
	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	13774000
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment For Sale Of Securities Included In Net Income Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentForSaleOfSecuritiesIncludedInNetIncomeNetOfTax	-75000
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	4.03
	us-gaap	Health Care Organization Patient Service Revenue Less Provision For Bad Debts HealthCareOrganizationPatientServiceRevenueLessProvisionForBadDebts	5242973000
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	3452000
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment For Sale Of Securities Included In Net Income Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentForSaleOfSecuritiesIncludedInNetIncomeBeforeTax	124000
	us-gaap	Payments Of Dividends Minority Interest PaymentsOfDividendsMinorityInterest	81978000
	us-gaap	Health Care Organization Other Revenue HealthCareOrganizationOtherRevenue	516368000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1958000
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	8314000
	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<div> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>7. Contingencies</b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The majority of the Company’s revenues are from government programs and may be subject to adjustment as a result of: (1) examination by government agencies or contractors, for which the resolution of any matters raised may take extended periods of time to finalize; (2) differing interpretations of government regulations by different Medicare contractors or regulatory authorities; (3) differing opinions regarding a patient’s medical diagnosis or the medical necessity of services provided; and (4) retroactive applications or interpretations of governmental requirements. In addition, the Company’s revenues from commercial payors may be subject to adjustment as a result of potential claims for refunds, as a result of government actions or as a result of other claims by commercial payors.</font></p> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"> <font style="FONT-FAMILY: Times New Roman" size="2"><font style="FONT-FAMILY: Times New Roman" size="2"><i>Inquiries by the Federal Government and Certain Related Civil Proceedings</i></font></font></p> <p style="PADDING-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2"><font style="FONT-FAMILY: Times New Roman" size="2"><u>2005 U.S. Attorney Investigation:</u> In March 2005, the Company received a subpoena from the U.S. Attorney’s Office for the Eastern District of Missouri in St. Louis. The subpoena required production of a wide range of documents relating to the Company’s operations, including documents related to, among other things, pharmaceutical and other services provided to patients, relationships with pharmaceutical companies, and financial relationships with physicians and joint ventures. The subpoena covers the period from December 1, 1996 through March 2005. In October 2005, the Company received a follow-up request for additional documents related to specific medical director and joint venture arrangements. In February 2006, the Company received an additional subpoena for documents, including certain patient records relating to the administration and billing of Epogen<font style="FONT-FAMILY: Times New Roman" size="1"><sup style="POSITION: relative; BOTTOM: 0.8ex; VERTICAL-ALIGN: baseline">®</sup></font> (EPO). In May 2007, the Company received a request for documents related to durable medical equipment and supply companies owned and operated by the Company. The Company cooperated with the inquiry and has produced the requested documents. The subpoenas were issued in connection with a joint civil and criminal investigation. It was possible that criminal proceedings could be initiated against the Company in connection with this investigation. Until recently, the Company had not received a communication from the St. Louis U.S. Attorney’s Office on this matter for nearly three years. In early October 2012, the Company announced that the government closed its investigation without filing any charges, without demanding any payments and without seeking any changes in Company policies.</font></font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2"><font style="FONT-FAMILY: Times New Roman" size="2"><u>Woodard Private Civil Suit:</u> In February 2007, the Company received a request for information from the Office of Inspector General, U.S. Department of Health and Human Services, or OIG, for documents relating to EPO claims submitted to Medicare. In August 2007, the Company received a subpoena from the OIG seeking similar documents. The requested documents relate to services provided from 2001 to 2004 by a number of the Company’s centers. The request and subpoena were sent from the OIG’s offices in Houston and Dallas, Texas. The Company cooperated with the inquiry and has produced all previously requested documents to date. The Company was contacted by the U.S. Attorney’s Office for the Eastern District of Texas, which stated that this was a civil investigation related to EPO claims. On July 6, 2009, the U.S. District Court for the Eastern District of Texas lifted the seal on the civil <i>qui tam</i> complaint related to these previous requests for information. The Company was subsequently served with a complaint by the relator, Ivey Woodard, purportedly on behalf of the federal government, under the <i>qui tam</i> provisions of the federal False Claims Act. The government did not intervene and is not actively pursuing this matter. The relator has been pursuing the claims independently and the parties have been engaged in active litigation. The complaint contains allegations relating to the Company’s EPO practices for the period from 1992 through 2010 and seeks monetary damages and civil penalties as well as costs and expenses. The court has ruled that claims earlier than 1996 are beyond the statute of limitations. The Company believes that there is some overlap between the subject of this complaint and the review of EPO utilization in the 2005 U.S. Attorney investigation described above. The Company publicly disclosed on July 3, 2012 that it had reached an agreement in principle to settle all allegations relating to claims arising out of this matter. In connection with this settlement, the Company accrued a charge of $78,000 in the second quarter of 2012, that consists of $55,000 for the settlement plus attorney fees and related expenses. The Company expects that the settlement will resolve federal program claims regarding EPO raised in the complaint relating to historical EPO practices dating back to 1997. The settlement is subject to certain conditions, such as court approval. Until the conditions and documentation are completed, there can be no assurance that this matter will in fact be resolved pursuant to the terms of the agreement in principle to settle.</font></font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2"><font style="FONT-FAMILY: Times New Roman" size="2"><u>Vainer Private Civil Suit:</u> In December 2008, the Company received a subpoena for documents from the OIG relating to the pharmaceutical products Zemplar, Hectorol, Venofer, Ferrlecit and EPO, as well as other related matters. The subpoena covered the period from January 2003 to December 2008. The Company was in contact with the U.S. Attorney’s Office for the Northern District of Georgia and the U.S. Department of Justice in Washington, DC, since November 2008 relating to this matter, and were advised that this was a civil inquiry. On June 17, 2009, the Company learned that the allegations underlying this inquiry were made as part of a civil complaint filed by individuals and brought pursuant to the <i>qui tam</i> provisions of the federal False Claims Act. On April 1, 2011, the U.S. District Court for the Northern District of Georgia ordered the case to be unsealed. At that time, the Department of Justice and U.S. Attorney’s Office filed a notice of declination stating that the U.S. would not be intervening and not pursuing the relators’ allegation in litigation. On July 25, 2011, the relators, Daniel Barbir and Dr. Alon Vainer, filed their amended complaint in the U.S. District Court for the Northern District of Georgia, purportedly on behalf of the federal government. The allegations in the complaint relate to the Company’s drug administration practices for Vitamin D and iron agents for a period from 2003 through 2010. The complaint seeks monetary damages and civil penalties as well as costs and expenses. The Company is vigorously defending this matter and intends to continue to do so. The Company can make no assurances as to the time or resources that will be needed to devote to this litigation or its final outcome.</font></font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2"><font style="FONT-FAMILY: Times New Roman" size="2"><u>2010 U.S. Attorney Physician Relationship Investigation:</u> In May 2010, the Company received a subpoena from the OIG’s office in Dallas, Texas. The civil subpoena covers the period from January 1, 2005 to May 2010, and seeks production of a wide range of documents relating to the Company’s operations, including documents related to, among other things, financial relationships with physicians and joint ventures. Some of the requested documents overlap with documents requested pursuant to the subpoena in the 2011 U.S. Attorney Physician Relationship Investigation described below. The Company is cooperating with the government and is producing the requested documents. The Company can make no assurances as to the time or resources that will be needed to devote to this litigation or its final outcome.</font></font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2"><font style="FONT-FAMILY: Times New Roman" size="2"><u>2011 U.S. Attorney Physician Relationship Investigation:</u> In August 2011, the Company announced it had learned that the U.S. Attorney’s Office for the District of Colorado would be looking into certain activities of the Company in connection with information being provided to a grand jury. The Company announced further that it understood that this investigation was at a very preliminary stage, and while its precise scope was unclear, it appeared to overlap, at least in part, with the 2010 U.S. Attorney Physician Relationship Investigation described above. Subsequent to the Company’s announcement of this 2011 U.S. Attorney Physician Relationship Investigation, it received a subpoena for documents which substantially overlaps with the subpoena in the 2010 U.S. Attorney Physician Relationship Investigation described above and covers the period from January 2006 to September 2011. The Company is cooperating with the government and is producing the requested documents. Certain current and former members of the Board and executives received subpoenas in November 2011 and thereafter to testify before the grand jury. The Company has received additional subpoenas for documents, and a number of other individuals have received subpoenas to testify before the grand jury. It is possible that criminal proceedings may be initiated against the Company in connection with this investigation. The Company can make no assurances as to the time or resources that will be needed to devote to this litigation or its final outcome.</font></font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2"><font style="FONT-FAMILY: Times New Roman" size="2"><u>2011 U.S. Attorney Medicaid Investigation:</u> In October 2011, the Company announced that it would be receiving a request for documents, which could include an administrative subpoena from the Office of Inspector General for the U.S. Department of Health and Human Services. Subsequent to the Company’s announcement of this 2011 U.S. Attorney Medicaid Investigation, the Company received a request for documents in connection with the inquiry by the U.S. Attorney’s Office for the Eastern District of New York. The request relates to payments for infusion drugs covered by Medicaid composite payments for dialysis. The Company believes this inquiry is civil in nature. The Company does not know the time period or scope. The Company understands that certain other providers that operate dialysis clinics in New York may be receiving or have received a similar request for documents. The Company is cooperating with the government and is producing the requested documents.</font></font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2"><font style="FONT-FAMILY: Times New Roman" size="2"><u>Clark Shareholder Derivative Civil Suit</u>: As the Company previously disclosed, on August 7, 2012, a shareholder derivative lawsuit was filed in the U.S. District Court for the District of Colorado against certain current and former directors and executives of the Company and against the Company, as nominal defendant. The complaint alleges, among other things, that certain of the Company’s current and past officers and directors breached fiduciary duties to the Company relating to the previously disclosed inquiries by the federal government and <i>qui tam</i> proceedings described above. On October 12, 2012, the parties filed a joint motion to stay the case for an indefinite period as in the best interests of the Company and to conserve judicial resources. On October 19, 2012, the Court denied the stay motion but ordered that the case be administratively closed, subject to being reopened upon a showing of good cause by any party.</font></font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2"><font style="FONT-FAMILY: Times New Roman" size="2">Except for the private civil complaints filed by the relators as described above, to the Company’s knowledge, no proceedings have been initiated against the Company at this time in connection with any of the inquiries by the federal government. Although the Company cannot predict whether or when proceedings might be initiated or when these matters may be resolved, it is not unusual for inquiries such as these to continue for a considerable period of time through the various phases of document and witness requests and on-going discussions with regulators. Responding to the subpoenas or inquiries and defending the Company in the relator proceedings will continue to require management’s attention and significant legal expense. Any negative findings in the inquiries or relator proceedings could result in substantial financial penalties or awards against the Company, exclusion from future participation in the Medicare and Medicaid programs and, to the extent criminal proceedings may be initiated against the Company, possible criminal penalties. At this time, the Company cannot predict the ultimate outcome of these inquiries, or the potential outcome of the relators’ claims (except as described above), or the potential range of damages, if any.</font></font></p> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"> <font style="FONT-FAMILY: Times New Roman" size="2"><font style="FONT-FAMILY: Times New Roman" size="2"><i>Other</i></font></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2"><font style="FONT-FAMILY: Times New Roman" size="2">The Company has received several notices of claims from commercial payors and other third parties related to historical billing practices and claims against DVA Renal Healthcare (formerly known as Gambro Healthcare), a subsidiary of the Company, related to historical Gambro Healthcare billing practices and other matters covered by its 2004 settlement agreement with the Department of Justice and certain agencies of the U.S. government. The Company has received no further indication that any of these claims are active, and some of them may be barred by applicable statutes of limitations. To the extent any of these claims might proceed, the Company intends to defend against them vigorously; however, the Company may not be successful and these claims may lead to litigation and any such litigation may be resolved unfavorably. At this time, the Company cannot predict the ultimate outcome of this matter or the potential range of damages, if any.</font></font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2"><font style="FONT-FAMILY: Times New Roman" size="2">A wage and hour claim, which has been styled as a class action, is pending against the Company in the Superior Court of California. The Company was served with the complaint in this lawsuit in April 2008, and it has been amended since that time. The lawsuit, as amended, alleges that the Company failed to provide meal periods, failed to pay compensation in lieu of providing rest or meal periods, failed to pay overtime, and failed to comply with certain other California Labor Code requirements. In September 2011, the court denied the plaintiffs’ motion for class certification. Plaintiffs have appealed that decision. The Company intends to continue to vigorously defend against these claims. Any potential settlement of these claims is not anticipated to be material to the Company’s consolidated financial statements.</font></font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2"><font style="FONT-FAMILY: Times New Roman" size="2">In October 2007, the Company was contacted by the Attorney General’s Office for the State of Nevada. The Attorney General’s Office informed the Company that it was conducting a civil and criminal investigation of the Company’s operations in Nevada and that the investigation related to the billing of pharmaceuticals, including EPO. In February 2008, the Attorney General’s Office informed the Company that the civil and criminal investigation had been discontinued. The Attorney General’s Office further advised the Company that Nevada Medicaid intended to conduct audits of end stage renal disease (ESRD) dialysis providers in Nevada and such audits would relate to the issues that were the subjects of the investigation. To the Company’s knowledge, no court proceedings have been initiated against the Company at this time. Any negative audit findings could result in a substantial repayment by the Company. At this time, the Company cannot predict the ultimate outcome of this matter or the potential range of damages, if any.</font></font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2"><font style="FONT-FAMILY: Times New Roman" size="2">In June 2004, DVA Renal Healthcare was served with a complaint filed in the Superior Court of California by one of its former employees who worked for its California acute services program. The complaint, which is styled as a class action, alleges, among other things, that DVA Renal Healthcare failed to provide overtime wages, defined rest periods and meal periods, or compensation in lieu of such provisions and failed to comply with certain other California Labor Code requirements. The parties reached an agreement last year to fully resolve this matter for an amount that did not materially impact the Company’s financial results. That settlement has now received final approval from the court. Settlement payments have been made to the class members. On September 18, 2012, the court found that the conditions in its order approving the settlement had been met, and that the matter is concluded.</font></font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2"><font style="FONT-FAMILY: Times New Roman" size="2">In addition to the foregoing, the Company is subject to claims and suits, including from time to time, contractual disputes and professional and general liability claims, as well as audits and investigations by various government entities, in the ordinary course of business. The Company believes that the ultimate resolution of any such pending proceedings, whether the underlying claims are covered by insurance or not, will not have a material adverse effect on its financial condition, results of operations or cash flows.</font></font></p> </div>
	us-gaap	Net Income Loss NetIncomeLoss	380178000
	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	39346000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	262138000
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	43000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	380178000
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	3.96
	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	6796000
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1374000
	us-gaap	Tax Benefit From Stock Options Exercised1 TaxBenefitFromStockOptionsExercised1	60252000
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1641000	shares
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	380178000
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-69108000
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	458638000
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	87223000
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1387000
	us-gaap	Payments To Acquire Businesses And Interest In Affiliates PaymentsToAcquireBusinessesAndInterestInAffiliates	419114000
	us-gaap	Contributions From Noncontrolling Interests ContributionsFromNoncontrollingInterests	19368000
	dva	Increase Decrease In Other Current Receivables And Other Current Assets IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets	-65047000
	dva	Proceeds From Repayments Of Long Term Debt ProceedsFromRepaymentsOfLongTermDebt	1170098000
	dva	Patient Care Costs PatientCareCosts	3916324000
	dva	Debt Expense DebtExpense	192584000
	dva	Adjustment Income Loss From Equity Method Investments AdjustmentIncomeLossFromEquityMethodInvestments	-10000
	dva	Adjustment Depreciation And Amortization AdjustmentDepreciationAndAmortization	234368000
	dva	Distributions From Equity Investments DistributionsFromEquityInvestments	2000
	dva	Changes From Net Income Attributable To Parent And Transfers From To Noncontrolling Interests ChangesFromNetIncomeAttributableToParentAndTransfersFromToNoncontrollingInterests	369413000
	dva	Segment Reporting Information Corporate Expenses SegmentReportingInformationCorporateExpenses	17771000
	dva	Gain Loss On Disposal Of Assets And Other Noncash Charges GainLossOnDisposalOfAssetsAndOtherNoncashCharges	17244000
	dva	Debt Expense And Redemption Charges DebtExpenseAndRedemptionCharges	192584000
	dva	Other Operating Expenses OtherOperatingExpenses	78000000
	dva	Income Loss From Continuing Operations Available To Common Stockholders Basic IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic	380178000
	dva	Income Loss From Continuing Operations Available To Common Stockholders Diluted IncomeLossFromContinuingOperationsAvailableToCommonStockholdersDiluted	380178000
	dva	Weighted Average Number Basic Shares Outstanding Adjustment WeightedAverageNumberBasicSharesOutstandingAdjustment	94306000	shares
	dva	Stock Issued Or Vested During Period Shares Stock Awards StockIssuedOrVestedDuringPeriodSharesStockAwards	3000	shares
	dva	Health Care Organization Revenue Before Provision For Uncollectible Accounts HealthCareOrganizationRevenueBeforeProvisionForUncollectibleAccounts	5926568000
	dva	Payments For Proceeds To Acquire Equity Method Investments And Other Assets PaymentsForProceedsToAcquireEquityMethodInvestmentsAndOtherAssets	1276000
	dva	Payments For Proceeds From Sale Of Investments In Securities And Other PaymentsForProceedsFromSaleOfInvestmentsInSecuritiesAndOther	-9188000
	dva	Payments For Proceeds Of Interest Rate Cap Premium And Other Deferred Financing Costs PaymentsForProceedsOfInterestRateCapPremiumAndOtherDeferredFinancingCosts	22189000
	dva	Provision For Doubtful Accounts On Patient Service Revenue ProvisionForDoubtfulAccountsOnPatientServiceRevenue	167227000
CY2012Q3	us-gaap	Debt Instrument Frequency Of Periodic Payment DebtInstrumentFrequencyOfPeriodicPayment	The New Senior Notes will pay interest on February 15 and August 15 of each year, beginning February 15, 2013.
CY2011Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-2831000
CY2011Q3	us-gaap	Costs And Expenses CostsAndExpenses	1439118000
CY2011Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	318712000
CY2011Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	26485000
CY2011Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	138192000
CY2011Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	126292000
CY2011Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	26485000
CY2011Q3	us-gaap	Minority Interest Period Increase Decrease MinorityInterestPeriodIncreaseDecrease	-179000
CY2011Q3	us-gaap	Share Based Compensation ShareBasedCompensation	13333000
CY2011Q3	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	164458000
CY2011Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.42
CY2011Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	1903000
CY2011Q3	us-gaap	Profit Loss ProfitLoss	161846000
CY2011Q3	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	1757830000
CY2011Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1729000	shares
CY2011Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	67558000
CY2011Q3	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment On Derivatives Included In Net Income Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentOnDerivativesIncludedInNetIncomeNetOfTax	2702000
CY2011Q3	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	-10869000
CY2011Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-2612000
CY2011Q3	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax	-3688000
CY2011Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	182638000
CY2011Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	95171225	shares
CY2011Q3	us-gaap	Minority Interest Change In Redemption Value MinorityInterestChangeInRedemptionValue	-17000
CY2011Q3	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	798000
CY2011Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	258662000
CY2011Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-9069000
CY2011Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.45
CY2011Q3	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	1669086000
CY2011Q3	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	1.48
CY2011Q3	us-gaap	Health Care Organization Patient Service Revenue Less Provision For Bad Debts HealthCareOrganizationPatientServiceRevenueLessProvisionForBadDebts	1619047000
CY2011Q3	us-gaap	Health Care Organization Other Revenue HealthCareOrganizationOtherRevenue	138783000
CY2011Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	93441620	shares
CY2011Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	2619000
CY2011Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2834000	shares
CY2011Q3	us-gaap	Net Income Loss NetIncomeLoss	135361000
CY2011Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	94204000
CY2011Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	135344000
CY2011Q3	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	1.45
CY2011Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	152777000
CY2011Q3	us-gaap	Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Net Of Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax	1076000
CY2011Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-902000
CY2011Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	135344000
CY2011Q3	dva	Patient Care Costs PatientCareCosts	1189638000
CY2011Q3	dva	Debt Expense DebtExpense	60848000
CY2011Q3	dva	Changes From Net Income Attributable To Parent And Transfers From To Noncontrolling Interests ChangesFromNetIncomeAttributableToParentAndTransfersFromToNoncontrollingInterests	135182000
CY2011Q3	dva	Debt Expense And Redemption Charges DebtExpenseAndRedemptionCharges	60848000
CY2011Q3	dva	Income Loss From Continuing Operations Available To Common Stockholders Basic IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic	138175000
CY2011Q3	dva	Income Loss From Continuing Operations Available To Common Stockholders Diluted IncomeLossFromContinuingOperationsAvailableToCommonStockholdersDiluted	138175000
CY2011Q3	dva	Weighted Average Number Basic Shares Outstanding Adjustment WeightedAverageNumberBasicSharesOutstandingAdjustment	93439000	shares
CY2011Q3	dva	Stock Issued Or Vested During Period Shares Stock Awards StockIssuedOrVestedDuringPeriodSharesStockAwards	3000	shares
CY2011Q3	dva	Health Care Organization Revenue Before Provision For Uncollectible Accounts HealthCareOrganizationRevenueBeforeProvisionForUncollectibleAccounts	1807869000
CY2011Q3	dva	Provision For Doubtful Accounts On Patient Service Revenue ProvisionForDoubtfulAccountsOnPatientServiceRevenue	50039000
CY2012Q3	us-gaap	Costs And Expenses CostsAndExpenses	1622107000
CY2012Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	340859000
CY2012Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	27829000
CY2012Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	144721000
CY2012Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	145820000
CY2012Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	27829000
CY2012Q3	us-gaap	Minority Interest Period Increase Decrease MinorityInterestPeriodIncreaseDecrease	-3089000
CY2012Q3	us-gaap	Share Based Compensation ShareBasedCompensation	10513000
CY2012Q3	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	172550000
CY2012Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.50
CY2012Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	2469000
CY2012Q3	us-gaap	Profit Loss ProfitLoss	172550000
CY2012Q3	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	1962966000
CY2012Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1655000	shares
CY2012Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	80586000
CY2012Q3	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment On Derivatives Included In Net Income Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentOnDerivativesIncludedInNetIncomeNetOfTax	2530000
CY2012Q3	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	-1741000
CY2012Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	201198000
CY2012Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	96634620	shares
CY2012Q3	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	819000
CY2012Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-135000
CY2012Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	271184000
CY2012Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	1099000
CY2012Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.52
CY2012Q3	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	1838363000
CY2012Q3	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	1.52
CY2012Q3	us-gaap	Health Care Organization Patient Service Revenue Less Provision For Bad Debts HealthCareOrganizationPatientServiceRevenueLessProvisionForBadDebts	1778560000
CY2012Q3	us-gaap	Health Care Organization Other Revenue HealthCareOrganizationOtherRevenue	184406000
CY2012Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	94979858	shares
CY2012Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	3064000
CY2012Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	236000	shares
CY2012Q3	us-gaap	Net Income Loss NetIncomeLoss	144721000
CY2012Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	98634000
CY2012Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	144721000
CY2012Q3	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	1.50
CY2012Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	173649000
CY2012Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	445000
CY2012Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	144721000
CY2012Q3	dva	Patient Care Costs PatientCareCosts	1340918000
CY2012Q3	dva	Debt Expense DebtExpense	70494000
CY2012Q3	dva	Changes From Net Income Attributable To Parent And Transfers From To Noncontrolling Interests ChangesFromNetIncomeAttributableToParentAndTransfersFromToNoncontrollingInterests	141632000
CY2012Q3	dva	Segment Reporting Information Corporate Expenses SegmentReportingInformationCorporateExpenses	1335000
CY2012Q3	dva	Debt Expense And Redemption Charges DebtExpenseAndRedemptionCharges	70494000
CY2012Q3	dva	Income Loss From Continuing Operations Available To Common Stockholders Basic IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic	144721000
CY2012Q3	dva	Income Loss From Continuing Operations Available To Common Stockholders Diluted IncomeLossFromContinuingOperationsAvailableToCommonStockholdersDiluted	144721000
CY2012Q3	dva	Weighted Average Number Basic Shares Outstanding Adjustment WeightedAverageNumberBasicSharesOutstandingAdjustment	94977000	shares
CY2012Q3	dva	Stock Issued Or Vested During Period Shares Stock Awards StockIssuedOrVestedDuringPeriodSharesStockAwards	3000	shares
CY2012Q3	dva	Health Care Organization Revenue Before Provision For Uncollectible Accounts HealthCareOrganizationRevenueBeforeProvisionForUncollectibleAccounts	2022769000
CY2012Q3	dva	Provision For Doubtful Accounts On Patient Service Revenue ProvisionForDoubtfulAccountsOnPatientServiceRevenue	59803000

Files In Submission

Name	View Source	Status
0001193125-12-443449-index-headers.html	Edgar Link	pending
0001193125-12-443449-index.html	Edgar Link	pending
0001193125-12-443449.txt	Edgar Link	pending
0001193125-12-443449-xbrl.zip	Edgar Link	pending
d413235d10q.htm	Edgar Link	pending
d413235dex121.htm	Edgar Link	pending
d413235dex311.htm	Edgar Link	pending
d413235dex312.htm	Edgar Link	pending
d413235dex321.htm	Edgar Link	pending
d413235dex322.htm	Edgar Link	pending
dva-20120930.xml	Edgar Link	completed
dva-20120930.xsd	Edgar Link	pending
dva-20120930_cal.xml	Edgar Link	unprocessable
dva-20120930_def.xml	Edgar Link	unprocessable
dva-20120930_lab.xml	Edgar Link	unprocessable
dva-20120930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DVA
DAVITA INC. Stock $dva

2012 Q4 Form 10-Q Financial Statement

#000119312512443449 Filed on October 31, 2012

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DVA DAVITA INC. Stock $dva

2012 Q4 Form 10-Q Financial Statement

#000119312512443449 Filed on October 31, 2012

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DVA
DAVITA INC. Stock $dva